Exclusive Summary

• Ranked in the top tier of global generic development with a 2026 US FDA filing plan, enabling partners to secure First-to-File or Day-1 launch opportunities.
• Backed by US FDA-level cGMP compliance and quality, providing a premium dossier that significantly accelerates regulatory approvals across RoW markets.
• Targets a massive prostate cancer market (>1.4 million global new cases annually) against a blockbuster brand projecting over €3 billion in peak sales.
• Offers best-in-class safety with exceptionally low CNS side effects compared to peers (like enzalutamide) and is highly recommended by NCCN guidelines as a first-line therapy.